Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Vaccine development stories

Nov 10, 2026

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources
00
Oct 28, 2026

IAVI receives up to $99 million US contract for Ebola vaccine development

Biomedical research organization IAVI was awarded $36 million under a US government contract worth up to $99 million to advance development of its single-dose Ebola vaccine.

Oct 28, 2026·2 sources
00
Oct 26, 2026

Congo Ebola cases surpass 10,000 as health worker killed in attack

Democratic Republic of Congo's Ebola outbreak has exceeded 10,000 confirmed cases, with violence against health workers intensifying after a nurse was killed responding to the epidemic.

Oct 26, 2026·2 sources
00
Oct 15, 2026

Osivax's flu vaccine OVX836 fails Phase 2b trial, company pivots to combination approach

French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.

Oct 15, 2026·2 sources
00
Oct 6, 2026

Bangladesh considers dengue vaccine trials as outbreak kills hundreds

Bangladesh is considering clinical trials for a dengue vaccine after hundreds of deaths and thousands of hospitalizations from the mosquito-borne disease. The outbreak has worsened through September, with at least 233 deaths reported and experts warning that weather conditions could fuel further spread.

Oct 6, 2026·3 sources
00
Oct 5, 2026

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 2026·3 sources
00
Oct 1, 2026

Lyme disease vaccine shows safety in children aged 5-17 in phase 3 trial

A four-dose series of an investigational Lyme disease vaccine demonstrated safety and tolerability in children and teens aged 5-17 years in phase 3 randomized controlled trial results presented at the American Academy of Pediatrics 2026 National Conference. The development comes as drugmakers race to create effective defenses against Lyme disease amid intensifying tick seasons.

Oct 1, 2026·3 sources
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Sep 13, 2026

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.

Sep 13, 2026·1 source
00
Aug 28, 2026

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
Aug 20, 2026

Moderna gains $45 billion in market value after cancer vaccine breakthrough

Moderna's stock surged following positive data on its mRNA cancer vaccine developed with Merck, restoring investor confidence and bringing shares to levels not seen since 2024.

Aug 20, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 5, 2026

UK Scientists Successfully Trial First 'Fridge-Free' Vaccines in Patients

British researchers have conducted the first successful clinical trials of vaccines that do not require refrigeration, a breakthrough that could address the problem of half of all vaccines being discarded due to cold chain failures.

Aug 5, 2026·3 sources
00
Aug 4, 2026

Moderna Begins First Human Trial of Vaccine Against Bundibugyo Ebola Strain Linked to Congo Outbreak

Moderna has initiated a Phase 1 clinical trial in Canada of mRNA-1469, an experimental vaccine targeting Bundibugyo ebolavirus, a strain of Ebola that has killed over 1,650 people and currently has no approved vaccine. Health Canada has authorized the trial and the first participants have already been vaccinated.

Aug 4, 2026·8 sources
00
Jul 30, 2026

Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak

Hilleman Laboratories, a Singapore-based partnership between Merck and Wellcome, is preparing to produce doses of an experimental vaccine targeting the rare Bundibugyo strain of Ebola amid a fast-spreading outbreak in the Democratic Republic of Congo.

Jul 30, 2026·1 source
00

Merseyside Woman Becomes First Patient Worldwide to Receive New Lung Cancer Vaccine in Clinical Trial

A lung cancer patient from Merseyside has become the first person in the world to receive a new experimental vaccine as part of an early-stage clinical trial involving 10 patients.

Jul 30, 2026
00
Jul 24, 2026

First Volunteer Vaccinated in World’s First Bundibugyo Ebola Vaccine Trial

Oxford University researchers administered the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola to a UK volunteer, as the deadly outbreak in the Democratic Republic of Congo has now killed over 1,000 people. Separate studies suggest existing Ebola vaccines may offer some cross-protection against this rare strain.

Jul 24, 2026·4 sources
00
Jul 16, 2026

Serum Institute of India to Manufacture Experimental TB Vaccine M72/AS01E in Partnership with Gates Medical Research Institute

The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.

Jul 16, 2026·3 sources
00
Jul 13, 2026

Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine Amid Congo Outbreak

The University of Oxford has begun the first human trial of a vaccine targeting Bundibugyo ebolavirus, accelerating efforts to combat an ongoing outbreak in the Democratic Republic of Congo. A US patient infected in Congo is being treated at a German hospital.

Jul 13, 2026·2 sources
00
Jul 9, 2026

Moderna Wins EU Contract for RSV Vaccine Supply

Moderna has secured a contract with the European Union to supply its respiratory syncytial virus (RSV) vaccine, expanding the company's vaccine portfolio beyond COVID-19.

Jul 9, 2026·1 source
00
Jul 6, 2026

Ebola outbreak in Democratic Republic of Congo reaches 1,561 cases with over 500 deaths

The Democratic Republic of Congo's 17th Ebola epidemic has now claimed at least 506 lives out of 1,561 confirmed cases, according to health officials. The outbreak is caused by the Bundibugyo virus strain, for which no vaccine or approved treatment currently exists, and frontline health workers are threatening to strike.

Jul 6, 2026·3 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
Apr 20, 2026

India Approves New Tuberculosis Vaccines for Adolescents Following Large Phase III Trial

India has approved new tuberculosis vaccines for adolescents, backed by a large, independent Phase III clinical trial led and funded by public science institutions. The vaccines represent a significant breakthrough in TB prevention, though officials note they are not a complete solution.

Apr 20, 2026·1 source
00
Apr 19, 2026

mRNA Cancer Vaccines Show Effectiveness Even Without Key Immune Cells in New Research

Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.

Apr 19, 2026·1 source
00
Apr 10, 2026

Two New Tuberculosis Vaccines Prove Safe But Fail to Provide Broad Protection in India Trial

A large clinical trial in India published in The BMJ found two new TB vaccines are safe for adults and children but do not offer protection against all forms of tuberculosis.

Apr 10, 2026·1 source
00

Top claims

  • ▪Bioconjugation streamlines conjugate vaccine manufacturing compared to traditional chemical attachment methods, offering a simpler approach designed to produce higher-quality vaccines targeting bacterial infections
  • ▪The acquisition of Omniose by AstraZeneca followed a three-year exclusive research collaboration between the two companies, with financial terms of the deal undisclosed
  • ▪Omniose's bioconjugation platform enables single E. coli cells to produce and link bacterial polysaccharide antigens to engineered carrier proteins in a single process

Subtopics

Vaccines and Immunization Policy21Vaccine development and innovation16Clinical trials12Infectious Disease and Outbreaks12Drug Approval and Clinical Trials9Drug Policy, Pricing & Approval9Ebola outbreak6Cancer immunotherapy5Outbreak-Driven Vaccination5Pharma5MRNA vaccine technology4Pharmaceutical Industry4Personalized medicine3Public healthcare3Biotech innovation2Cancer & Oncology2Cancer treatment breakthroughs2Clinical evaluation2Clinical Trial Design & Evaluation2Ebola outbreak in the Democratic Republic of the Congo 20262Infectious disease prevention2Medical innovation2Adolescent health1Antimicrobial resistance1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories